Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Short term Debt (2016 - 2025)

Guided Therapeutics' Short term Debt history spans 13 years, with the latest figure at $79000.0 for Q3 2025.

  • For Q3 2025, Short term Debt fell 93.01% year-over-year to $79000.0; the TTM value through Sep 2025 reached $79000.0, down 93.01%, while the annual FY2024 figure was $118000.0, N/A changed from the prior year.
  • Short term Debt for Q3 2025 was $79000.0 at Guided Therapeutics, up from $60000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $1.1 million in Q2 2024 and bottomed at $17000.0 in Q4 2022.
  • The 4-year median for Short term Debt is $66500.0 (2022), against an average of $228928.6.
  • The largest annual shift saw Short term Debt skyrocketed 214.29% in 2021 before it tumbled 94.69% in 2025.
  • A 4-year view of Short term Debt shows it stood at $88000.0 in 2021, then tumbled by 80.68% to $17000.0 in 2022, then soared by 594.12% to $118000.0 in 2024, then crashed by 33.05% to $79000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Short term Debt are $79000.0 (Q3 2025), $60000.0 (Q2 2025), and $66000.0 (Q1 2025).